RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment

DNA methyltransferases expression in normal tissues and various human cancer cell lines, xenografts and tumors.

(2019) Richard J Honeywell et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

Emerging Roles of Nucleoside Transporters

(2018) Marçal Pastor-Anglada et al.   Frontiers in Pharmacology

Preliminary results from an ongoing phase 2a study of RX-3117, an oral nucleoside analogue to treat advanced urothelial cancer (aUC).

(2018) Jacob Adashek et al.   JOURNAL OF CLINICAL ONCOLOGY

TAS-106: Preclinical, Clinical and Beyond

(2017) Maen Abdelrahim et al.   ONCOLOGY

Global temporal patterns of pancreatic cancer and association with socioeconomic development

(2017) Martin C. S. Wong et al.   Scientific Reports

The pivotal role of uridine-cytidine kinases in pyrimidine metabolism and activation of cytotoxic nucleoside analogues in neuroblastoma

(2016) André B.P. van Kuilenburg et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective

(2016) Joseph Ciccolini et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Sensitive liquid chromatography mass spectrometry (LC-MS) assay reveals novel insights on DNA methylation and incorporation of gemcitabine, its metabolite difluorodeoxyuridine, deoxyuridine, and RX-3117 into DNA

(2016) Richard J. Honeywell et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

The radiosensitizing effect of fluorocyclopentenyl-cytosine (RX-3117) in ovarian and lung cancer cell lines

(2016) Dzjemma Sarkisjan et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

The Cytidine Analog Fluorocyclopentenylcytosine (RX-3117) Is Activated by Uridine-Cytidine Kinase 2

(2016) Dzjemma Sarkisjan et al.   PLoS One

The druggability of intracellular nucleotide-degrading enzymes

(2015) Chiara Rampazzo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Overall survival and renal function after partial and radical nephrectomy among older patients with localised renal cell carcinoma: A propensity-matched multicentre study

(2015) Jae Seung Chung et al.   EUROPEAN JOURNAL OF CANCER

Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies

(2014) Magali Svrcek et al.   HISTOPATHOLOGY

Novel Developments in the Use of Antimetabolites

(2014) Godefridus J. Peters   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360)

(2013) Godefridus J. Peters et al.   INVESTIGATIONAL NEW DRUGS

Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer

(2013) Helmut Oettle et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity

(2013) Elizabeth Poplin et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations

(2012) Maha Elnaggar et al.   CURRENT PHARMACEUTICAL DESIGN

Fluorocyclopentenyl-cytosine with Broad Spectrum and Potent Antitumor Activity

(2012) Won Jun Choi et al.   JOURNAL OF MEDICINAL CHEMISTRY

Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models

(2010) Andries M. Bergman et al.   INVESTIGATIONAL NEW DRUGS

Decitabine in the treatment of myelodysplastic syndromes

(2009) Fabio PS Santos et al.   Expert Review of Anticancer Therapy